Breaking News

India Approved Houston Co-Developed COVID-19 Vaccine

December 28, 2021 • 10:45 am CST
(Precision Vaccinations News)

India-based Biological E. Limited (BE) today announced that its CorbeVax protein sub-unit vaccine against COVID-19 received approval from the Drugs Controller General of India (DGCI).

BE developed the CorbeVax vaccine in collaboration with the Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine in Houston, Texas.

CorbeVax is a “recombinant protein sub-unit” vaccine developed from the receptor-binding domain of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum.

The adjuvant helps the body build an immune response against the SARS-CoV-2 coronavirus.

“Our scientists at Texas Children’s Hospital and Baylor College of Medicine are thrilled to help in the development of this vaccine, possibly the first covid vaccine specifically designed for global health,” commented Dr. Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children’s Hospital Centre for Vaccine Development, in a press statement issued on December 28, 2021.

BE plans to complete production at a rate of 75 million doses per month, anticipating about 100 million doses per month from February 2022.

These capacities will enable the Hyderabad-based company to deliver 300 million doses as promised to the Government of India.

Biological E. Limited is headquartered in Hyderabad, India, and was founded in 1953. BE was the first private sector biological products company in India and the first pharmaceutical company in Southern India.

BE supplies its vaccines to over 100 countries, and its therapeutic products are sold in India and the USA. BE currently has eight WHO-prequalified vaccines in its portfolio.

Our Trust Standards: Medical Advisory Committee

Share